Cargando…

TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is an immunosuppressive receptor expressed on the surface of immune cells, suppressing immune responses by activating the intracellular negative regulatory signals. TIGIT plays an important role in the pathogenes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Qi, Wang, Lei, Yuan, Maoling, Jin, Xiaohong, Chen, Zhiming, Wu, Changping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511404/ https://www.ncbi.nlm.nih.gov/pubmed/34659197 http://dx.doi.org/10.3389/fimmu.2021.688961

Ejemplares similares

TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer
por: Chen, Yaping, et al.
Publicado: (2022)

CD226 and TIGIT Cooperate in the Differentiation and Maturation of Human Tfh Cells
por: Yasutomi, Motoko, et al.
Publicado: (2022)

Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis
por: Deng, Chuiwen, et al.
Publicado: (2020)

Co-Expression of TIGIT and Helios Marks Immunosenescent CD8(+) T Cells During Aging
por: Pieren, Daan K. J., et al.
Publicado: (2022)

Analysis of the Characteristics of TIGIT-Expressing CD3(−)CD56(+)NK Cells in Controlling Different Stages of HIV-1 Infection
por: Zhang, Xin, et al.
Publicado: (2021)

TIGIT-Fc as a Potential Therapeutic Agent for Fetomaternal Tolerance
por: Fu, Wenyan, et al.
Publicado: (2021)

Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8(+) T Cells
por: Zhou, Xiu-Man, et al.
Publicado: (2018)

TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
por: Yue, Chenran, et al.
Publicado: (2022)

Prognostic value of CD155/TIGIT expression in patients with colorectal cancer
por: Murakami, Daisuke, et al.
Publicado: (2022)

Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals
por: Yin, Xiaowan, et al.
Publicado: (2018)

TIGIT Deficiency Protects Mice From DSS-Induced Colitis by Regulating IL-17A–Producing CD4(+) Tissue-Resident Memory T Cells
por: Chen, Binfeng, et al.
Publicado: (2022)

Increased frequency of TIGIT+ CD4 T Cell subset in autoantibody-positive first-degree relatives of patients with rheumatoid arthritis
por: Anaparti, Vidyanand, et al.
Publicado: (2022)

Expression of Senescence Marker TIGIT Identifies Polyfunctional Donor-Reactive CD4+ T Cells Preferentially Lost After Kidney Transplantation
por: van der List, Amy C. J., et al.
Publicado: (2021)

The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56(bright) NK cells
por: Ziegler, Annerose E., et al.
Publicado: (2023)

Use of aspirin in the prevention of colorectal cancer through TIGIT‐CD155 pathway
por: Ma, Bin, et al.
Publicado: (2019)

TIGIT-related transcriptome profile and its association with tumor immune microenvironment in breast cancer
por: Zhang, Qin, et al.
Publicado: (2021)

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
por: Ge, Zhouhong, et al.
Publicado: (2021)

Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT
por: Zeven, Katty, et al.
Publicado: (2023)

Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2023)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors
por: Yang, Fan, et al.
Publicado: (2023)

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
por: Yeo, Jinah, et al.
Publicado: (2021)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021)

Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation
por: Han, Jin-Hwan, et al.
Publicado: (2020)

Prognostic value of TIGIT in East Asian patients with solid cancers: A systematic review, meta-analysis and pancancer analysis
por: Li, Sicong, et al.
Publicado: (2022)

Multi-omics analyses of glucose metabolic reprogramming in colorectal cancer
por: Huang, Maosen, et al.
Publicado: (2023)

TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma
por: Raphael, Itay, et al.
Publicado: (2021)

Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer
por: Peng, Hui, et al.
Publicado: (2022)

Corrigendum: Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation
por: Han, Jin-Hwan, et al.
Publicado: (2020)

The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer
por: Chen, Yaping, et al.
Publicado: (2021)

Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity
por: Smith, Alyson J., et al.
Publicado: (2023)

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation
por: Worboys, Jonathan D., et al.
Publicado: (2023)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
por: Chen, Xin, et al.
Publicado: (2022)

Clinical Remission of Sight-Threatening Non-Infectious Uveitis Is Characterized by an Upregulation of Peripheral T-Regulatory Cell Polarized Towards T-bet and TIGIT
por: Gilbert, Rose M., et al.
Publicado: (2018)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
por: Maas, Ralph Ja, et al.
Publicado: (2020)

Glucose Metabolism: The Metabolic Signature of Tumor Associated Macrophage
por: Zhang, Qi, et al.
Publicado: (2021)

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy
por: Jin, Hyung-seung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kfv31q08unms1ec58kdbbcs3ud